89bio(US:ETNB)2020-11-13 00:15Financial Performance - The company reported a net loss of $14.6 million for the three months ended September 30, 2020, compared to a net loss of $18.7 million for the same period in 2019, representing a decrease of $4.1 million [96]. - Total operating expenses for Q3 2020 were $14.4 million, up from $8.2 million in Q3 2019, indicating an increase of $6.2 million [96]. - Total operating expenses for the nine months ended September 30, 2020, were $36.8 million, an increase of $19.8 million, or 116%, from $17.0 million for the same period in 2019 [101]. - Net cash used in operating activities was $32.2 million for the nine months ended September 30, 2020, compared to $14.3 million for the same period in 2019 [117]. - Other expenses, net decreased by $10.3 million to $0.2 million for the three months ended September 30, 2020, from $10.5 million in the prior year [99]. Research and Development - Research and development expenses increased to $11.2 million in Q3 2020 from $6.7 million in Q3 2019, reflecting an increase of $4.5 million [96]. - The company expects research and development expenses to increase substantially as it continues to invest in the development of BIO89-100 and future product candidates [91]. - Research and development expenses increased by $4.5 million, or 68%, to $11.2 million for the three months ended September 30, 2020, compared to $6.7 million for the same period in 2019 [97]. - Research and development expenses for the nine months ended September 30, 2020, increased by $13.3 million, or 94%, to $27.4 million from $14.2 million in the prior year [102]. - The company successfully completed a Phase 1b/2a clinical trial for BIO89-100, showing a relative reduction in liver fat of up to 60% versus baseline and up to 70% versus placebo [76]. - A Phase 2b trial for NASH patients is planned to be initiated in the first half of 2021, alongside a new paired-biopsy histology cohort [77]. - The ongoing COVID-19 pandemic may disrupt clinical trials and impact development timelines, including the Phase 2 trial in SHTG patients [86]. - The company plans to increase research and development expenses substantially for the foreseeable future as it continues clinical development [110]. Financial Position - As of September 30, 2020, the company had cash, cash equivalents, and short-term investments totaling $219.2 million, expected to meet cash requirements through Q2 2023 [84]. - The company has an accumulated deficit of $110.5 million as of September 30, 2020, and anticipates continued significant expenses as it advances BIO89-100 through clinical trials [85]. - The company had available cash and cash equivalents of $219.2 million as of September 30, 2020, with an accumulated deficit of $110.5 million [106]. - The company expects existing cash and short-term investments to fund operations through the second quarter of 2023 [111]. - Net cash provided by financing activities was $158.2 million for the nine months ended September 30, 2020, primarily from public offerings of common stock [122]. Accounting and Compliance - The company has not entered into any off-balance sheet arrangements and does not hold any interests in variable interest entities [125]. - There have been no significant changes in critical accounting policies and estimates compared to the previous annual report, except as noted in the condensed consolidated financial statements [126]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay adopting new or revised accounting standards until they apply to private companies [127]. - The extended transition period under the JOBS Act may result in the company's financial statements being less comparable to those of companies that comply with new accounting pronouncements [128]. Administrative Expenses - General and administrative expenses rose by $1.7 million, or 112%, to $3.2 million for the three months ended September 30, 2020, from $1.5 million in the prior year [98].